Immunome(IMNM) - 2024 Q4 - Annual Results

Exhibit 99.1 Immunome Reports Full Year 2024 Financial Results and Provides Business Update 3/19/2025 BOTHELL, Wash. – Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in- class targeted cancer therapies, today announced financial results for the full year ended December 31, 2024 and provided a business update. "Immunome's efficient execution in 2024 laid the foundation for a productive 2025," said Clay B. Siegall, Ph.D., President and Chief Executive Offi ...